ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Plasmapheresis"

  • 2018 American Transplant Congress

    Long-Term Success of Treatment for Cardiac Transplant AMR May Depend Upon Suppressing Class II Donor Specific Antibodies

    J. Hofmann,1 D. Weisshaar,2 D. Kiprov.3

    1Dept of Medicine, California Pacific Medical Center, San Francisco, CA; 2Dept of Medicine, Kaiser Permanente, Santa Clara, CA.

    Antibody mediated rejection (AMR) in cardiac transplant (tspt) patients (pts) is primarily mediated by donor specific antibodies (DSAs) and associated with reduced long-term graft survival.…
  • 2018 American Transplant Congress

    Acute Antibody Mediated Rejection Treatment Impact on Class I and Class II Anti-HLA Antibodies in Pediatric Kidney Transplant Recipients

    E. Kincaide,1,2,3 K. Hitchman,1,3 R. Hall,1,2,3 I. Yamaguchi,3 B. Crowther.1,2,3

    1University Health System, San Antonio, TX; 2College of Pharmacy, Pharmacotherapy Division, The University of Texas at Austin, Austin, TX; 3UT Health San Antonio, San Antonio, TX.

    Purpose: Characterize class I and class II donor specific antibodies (DSA) response to acute antibody mediated rejection (AMR) treatment in pediatric kidney transplant recipients (KTR).Methods:…
  • 2018 American Transplant Congress

    Recurrence of Focal Segmental Glomerulosclerosis (FSGS) and Response to Prolonged Plasmapheresis Therapy: A Single Center Pediatric Experience

    A. Bobrowski, D. Matossian.

    Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL.

    FSGS is the most common glomerular cause of ESKD in pediatric patients. The risk of recurrence after kidney transplant (KT) is 30-60%, and half of…
  • 2018 American Transplant Congress

    Efficacy and Safety of Acute Antibody Rejection Treatment in Pediatric Kidney Transplant Recipients

    E. Kincaide,1,2,3 K. Hitchman,1,3 R. Hall,1,2,3 I. Yamaguchi,3 B. Crowther.1,2,3

    1University Health System, San Antonio, TX; 2College of Pharmacy, Pharmacotherapy Division, The University of Texas at Austin, San Antonio, TX; 3UT Health San Antonio, San Antonio, TX.

    Purpose: Evaluate the efficacy and safety of acute antibody mediated rejection (AMR) treatment modalities in pediatric kidney transplant recipients (KTR).Methods: A single-center retrospective chart review…
  • 2018 American Transplant Congress

    Preemptive Plasma Therapy and Eculizumab (ECU) Rescue for Atypical Hemolytic Uremic Syndrome (aHUS) Relapse Following Kidney Transplantation (KTX)

    C. Aigner,1,2 G. Böhmig,1 F. Eskandary,1 M. Gaggl,1 R. Kain,2 R. Sunder-Plassmann,3 Z. Prohaszka,4 A. Schmidt,1 G. Sunder-Plassmann.1

    1Division of Nephrology and Dialysis, Medical University Vienna, Vienna, Austria; 2Clinical Institute of Pathology, Medical University Vienna, Vienna, Austria; 3Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria; 43rd Department of Medicine, Semmelweis University, Budapest, Hungary.

    Introduction: KTX in aHUS patients is associated with a high rate of relapse and graft loss. Here, we report on seven aHUS cases with end-stage…
  • 2018 American Transplant Congress

    Treatment Outcomes of FSGS Recurrence

    J. Mansur,1 D. Chang,2 G. Medeiros,1 M. Cristelli,1 L. Viana,1 S. Stopa,1 C. Felipe,1 G. Kirsztajn,1 H. Tedesco-Silva.1

    1Hospital do Rim, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; 2Hospital Nacional Cayetano Heredia, Universidad Peruana Cayetano Heredia, Lima, Peru.

    Background: Recurrence of FSGS (focal segmental glomerulosclerosis) after kidney transplant occurs in 30% of adults and up to 80% of children and has impact on…
  • 2018 American Transplant Congress

    Modified Protocol for ABO-Incompatible Living Donor Liver Transplantation with Rituximab and Intravenous Immunoglobulin without Plasma Exchange

    B-.G. Na, E. Lee, S. Kim, S. Park.

    Center for Liver Cancer, National Cancer Center, Il-san Donggu, Goyang, Republic of Korea.

    Purpose: Since a variety of desensitization strategies including rituximab, intravenous immunoglobulin (IVIG), and plasma exchange (PE) have been introduced, the survival and outcomes of recipients…
  • 2017 American Transplant Congress

    Renal Transplant Outcomes in Primary FSGS Compared with Other Recipients: A National Review of the Irish Transplant Registry.

    S. Cormican,1 C. Kennedy,1,2 P. O'Kelly,1 B. Doyle,3 A. Dorman,3 P. Conlon.1,2

    1Nephrology, Beaumont Hospital, Dublin, Ireland; 2Medicine, Royal College of Surgeons, Dublin, Ireland; 3Pathology, Beaumont Hospital, Dublin, Ireland

    Primary focal segmental glomerular sclerosis (p-FSGS) raises specific peri-transplant concerns, one of which is disease recurrence (r-FSGS). We aimed to compare transplant outcomes in patients…
  • 2017 American Transplant Congress

    Pre-Operative Desensitization for Live Donor Liver Transplantation with Strong Donor-Specific Antibodies.

    M. Fujiki,1 K. Hashimoto,1 A. Zhang,2 F. Aucejo,1 C. Quintini,1 T. Diago,1 B. Eghtesad,1 C. Miller.1

    1General Surgery, Cleveland Clinic, Cleveland, OH; 2Allogen Laboratories, Cleveland Clinic, Cleveland, OH

    Background: Presence of strong donor-specific antibodies (DSA) (MFI>4000) likely results in uncomplicated short-term outcome in whole liver transplants due to absorption of DSA by the…
  • 2017 American Transplant Congress

    Anti-CD25mAb Sparing Immunosuppressive Regimen Suppressed Recurrence of Post-Transplant Focal Segmental Glomerular Sclerosis- A Single Center Experience.

    H. Harada, Y. Wada, N. Fukuzawa.

    Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan

    INTRODUCTION: The rate of recurrence of primary focal segmental glomerular sclerosis (FSGS) is problematic, because it often results in very early serious urinary protein secretion…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences